ERBB2 and neoplasm: Recent studies have demonstrated the effectiveness of HER2-targeted CAR-T therapy against HER2+ tumor cells, leading to shrinkage of tumors, elimination of CRC xenografts, protection against recurrence, and increased survival benefit in comparison with control (109).